TE-8105 drug development was selected as a significant case of the Center for Drug Evaluation (CDE), Taiwan
編輯器
"The development of the novel drug, TE-8105, the glucagon-like peptide-1 receptor agonist" was selected as a significant case of the Center for Drug Evaluation (CDE), Taiwan.
